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Abstract
Introduction Breast cancer subtyping and prognosis have been
studied extensively by gene expression profiling, resulting in
disparate signatures with little overlap in their constituent genes.
Although a previous study demonstrated a prognostic
concordance among gene expression signatures, it was limited
to only one dataset and did not fully elucidate how the different
genes were related to one another nor did it examine the
contribution of well-known biological processes of breast
cancer tumorigenesis to their prognostic performance.
Method To address the above issues and to further validate
these initial findings, we performed the largest meta-analysis of
publicly available breast cancer gene expression and clinical
data, which are comprised of 2,833 breast tumors. Gene
coexpression modules of three key biological processes in
breast cancer (namely, proliferation, estrogen receptor [ER],
and HER2 signaling) were used to dissect the role of
constituent genes of nine prognostic signatures.
Results Using a meta-analytical approach, we consolidated the
signatures associated with ER signaling, ERBB2 amplification,
and proliferation. Previously published expression-based
nomenclature of breast cancer 'intrinsic' subtypes can be
mapped to the three modules, namely, the ER-/HER2- (basal-
like), the HER2+ (HER2-like), and the low- and high-proliferation
ER+/HER2- subtypes (luminal A and B). We showed that all nine
prognostic signatures exhibited a similar prognostic
performance in the entire dataset. Their prognostic abilities are
due mostly to the detection of proliferation activity. Although ER-
status (basal-like) and ERBB2+ expression status correspond to
bad outcome, they seem to act through elevated expression of
proliferation genes and thus contain only indirect information
about prognosis. Clinical variables measuring the extent of
tumor progression, such as tumor size and nodal status, still add
independent prognostic information to proliferation genes.
Conclusion This meta-analysis unifies various results of
previous gene expression studies in breast cancer. It reveals
connections between traditional prognostic factors, expression-
based subtyping, and prognostic signatures, highlighting the
important role of proliferation in breast cancer prognosis.Page 1 of 11
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Breast cancer is the disease most extensively studied by gene
expression profiling of primary tumors from patient populations
[1-21]. Despite this effort, the research results are still frag-
mented. Disparate signatures have been proposed, either
directly from breast cancer expression profiles [10-
12,18,19,21,22] or translated from model systems [1,23,24],
with little agreement in the constituent genes. Fan and col-
leagues [25] recently compared the prognostic ability of the
intrinsic subtypes and four prognostic signatures in 295
patients. They noted concordance in the risk classification,
which suggests potential equivalence between some of these
signatures. However, these signatures have been examined in
only one dataset and the study did not fully elucidate how the
different genes were related to one another nor did it examine
the contribution of well-known biological processes of breast
cancer tumorigenesis to their prognostic performance.
To address these issues, we undertook the largest meta-anal-
ysis of publicly available gene expression and clinical data,
which are comprised of 2,833 breast tumors [1-21]. We used
the concept of 'coexpression' modules (comprehensive lists of
genes with highly correlated expression) associated with
important biological processes in breast cancer to reveal the
common thread connecting molecular subtyping and several
prognostic signatures. Their prognostic values, adjusted for
the conventional clinicopathological variables, were studied in
a database of 2,833 patients with breast cancer in order to
arrive at solid conclusions. Finally, we went a step further to
characterize the constituent genes of these signatures and to
study how they contribute to their prognostic power.
Materials and methods
Detailed descriptions of the methods can be found in Addi-
tional data file 1. A brief summary is outlined here.
Preparation of expression data
We collected publicly available datasets from journal articles
and repositories such as Gene Expression Omnibus (GEO)
and ArrayExpress, selecting those with a medium to large sam-
ple size (Table 1). Since publications sometimes used the
same patients, datasets with unique patients were introduced
(identified by the 'dataset symbols' in Table 1) by merging
some original datasets or removing redundant patients. The
collection includes datasets produced on whole-genome
microarrays, small diagnostic arrays, and reverse transcription-
polymerase chain reaction panels, totaling 2,833 expression
profiles. Hybridization probes were mapped to Entrez GeneID
[26] through sequence alignment against RefSeq mRNA in
the (NM) subset, similar to the approach of Shi and colleagues
[27], using RefSeq version 21 (2007.01.21) and Entrez data-
base version 2007.01.21. When multiple probes were
mapped to the same GeneID, the one with the highest vari-
ance in a particular dataset was selected to represent the
GeneID. The numbers of distinct GeneIDs obtained for each
dataset are shown in Table 1. The normalized, log-transformed
expression measures as published by the original studies were
used. Meta-analyses were performed on the union of all
17,198 genes. Summary statistics of absent genes were con-
sidered as missing values. Summaries of the availability and
compositions of important clinical variables for each dataset
are shown in Figure 1 of Additional data file 2.
Identifying coexpression modules
The expression levels of the prototype genes on the log2 scale
were used as explanatory variables in multiple regression with
the Gaussian error model, using the following equation (gene
symbols stand for their log expression, and coefficients are
omitted for clarity):
Yi = ESR1 + ERBB2 + AURKA,
where the response variable Yi is the expression of gene i. This
model is fitted separately for each gene i in the array. The asso-
ciation between gene i and prototype j (in the presence of or
conditional on all other prototypes) is tested using the t statis-
tic for each coefficient. Because the t statistics for different
datasets have different degrees of freedom, we put them all on
the same scale by transforming them to the corresponding
cumulative probabilities and then to z scores using the inverse
standard normal cumulative distribution function. The z scores
were combined meta-analytically across datasets using the
'inverse normal method'. The linear model above was fitted
separately to each gene in each dataset, and the z scores
were combined meta-analytically over multiple studies using
the inverse normal method [28]. To select genes that are most
strongly associated with the prototypes, we use a stringent cri-
terion of |z| ≥ 16, which is well above |z| ≈ 5 that corresponds
to a Bonferroni-corrected P value of 0.05.
Module scores
For a specific dataset, the module score is computed for each
sample as
where xi is the expression of a gene in the module that is
present in the dataset's platform. wi is either +1 or -1, depend-
ing on the sign of the z score of the association with the
prototypes.
Clustering and multimodality tests
To cluster the tumors based on the ESR1 and ERBB2 module
scores, Gaussian mixture models [29] with equal and diagonal
variance for all clusters were fitted. For testing multimodality,
we used the likelihood ratio test statistics between the fitted
model for the tested number of components, k, versus the
alternative model with k - 1 components. The statistical signif-
icance of the number of components was assessed by para-
module score = ∑ ∑w x w
i
i
i
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Available online http://breast-cancer-research.com/content/10/4/R65metric bootstrapping. Each tumor was automatically classified
as estrogen receptor-negative (ER-)/HER2+, HER2+, or ER+
using the maximum posterior probability of membership in the
clusters.
Survival analysis
Survival curves and 5-year survival rates in forest plots were
based on Kaplan-Meier estimates, with the Greenwood
method used for computing the 95% confidence intervals
[30]. Hazard ratios between two groups were calculated using
Cox regression. Stratified Cox regression was used to com-
pute total hazard ratios in forest plots and multivariate analysis,
using the dataset as the stratum indicator, thus allowing for dif-
ferent baseline hazard functions between cohorts. Cox regres-
sion was also used to compute gene-by-gene associations
with survival, treating the log expression measures as continu-
ous explanatory variables. The gene-wise z scores were com-
bined across datasets using the inverse normal meta-
analytical methods. Distant relapse-free survival (DRFS) was
considered as an event for our survival analysis, which
includes distant recurrence, death from breast cancer, death
from a cause other than breast cancer, and death from an
unknown cause.
Results
Prototype-based coexpression module analysis
To perform this meta-analysis including several heterogeneous
datasets and different microarray platforms, we used the con-
cept of coexpression modules. To identify these modules, we
applied a supervised approach whereby three 'prototype'
genes representing three key biological processes in breast
cancer (namely, proliferation, ER, and HER2 amplification sig-
naling) were selected. The genes chosen as their prototypes
were, respectively, ESR1, ERBB2, and AURKA (aurora-
related kinase 1, also known as STK6 or STK15).
Using the meta-analysis scheme described above, we were
able to identify genes whose expression was significantly
associated with each chosen prototype (Additional data file 3).
The coexpression patterns of the genes are shown by
heatmaps in Figure 2 of Additional data file 2. Each module
contains highly correlated or anticorrelated genes, as shown
by the vertical color patterns. The annotation of the modules
Figure 1
Breast tumor characterization using module scorest tu or characterization using module scores. (a) Joint distribution between the estrogen and ERBB2 amplification scores in example 
datasets. Clusters are identified by Gaussian mixture models with three components. The ellipses correspond to the 95% cumulative probability 
around the cluster centers. The clusters are designated as tumor types ER-/ERBB2-, HER2+, and ER+/HER2-. HER2+ tumors show intermediate 
estrogen scores. (b) Dot histograms showing dependence of proliferation score on the subtypes. The median and quartiles for each group are 
shown by the box plot. ER-/ERBB2- and HER2+ tumors show high proliferation scores, whereas ER+/HER2- tumors show a wide range of prolifera-
tion scores. The distributions of the intrinsic subtypes (colored dots), BRCA1 mutations, and p53 mutations are shown in datasets where they are 
available. ER, estrogen receptor.Page 3 of 11
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processes, as many ER-related, HER2-related, and prolifera-
tion genes were included in the ER and HER2 signaling and
proliferation modules, respectively. For our further analysis, the
correlated gene expression measures in a module (which pro-
vide redundant information) are averaged into a single number
called a 'module score'.
Table 1
Publicly available gene expression data from breast cancer studies
Dataset symbol Number of arrays Institution Reference(s) Platform Data source Number of GeneIDs
Genomic platforms
NKI 337 Nederlands Kanker 
Instituut (Amsterdam, The 
Netherlands)
[19,20] Agilent Author's website 13,120
EMC 286 Erasmus Medical Center 
(Rotterdam, The 
Netherlands)
[21] Affymetrix U133A GEO: GSE2034 11,837
UPP 249 Karolinksa Institute 
(Uppsala, Sweden)
[3,11] Affymetrix U133A,B GEO: GSE4922 15,684
STOCK 159 Karolinska Institute 
(Stockholm, Sweden)
[3,13] Affymetrix U133A,B GEO: GSE1456 15,684
DUKE 171 Duke University (Durham, 
NC, USA)
[8] Affymetrix U95Av2 Author's website 8,149
UCSF 161 + 8 University of California at 
San Francisco (USA)
[9] cDNA Author's website 6,178
UNC 143 + 10 University of North 
Carolina (Chapel Hill, NC, 
USA)
[7] Agilent HuA1 Author's website 13,784
NCH 135 Nottingham City Hospital 
(Nottingham, UK)
[12] Agilent HuA1 AE: E-UCON-1 13,784
STNO 115 + 7 Stanford University (Palo 
Alto, CA, USA)/Norwegian 
Radium Hospital (Oslo, 
Norway)
[16] cDNA Author's website 5,614
JRH1 99 John Radcliffe Hospital 
(Oxford, UK)
[17] cDNA Journal's website 4,112
JRH2 61 John Radcliffe Hospital [18] Affymetrix U133A GEO: GSE2990 11,837
MGH 60 Massachusetts General 
Hospital (Boston, MA, 
USA)
[10] Agilent GEO: GSE1379 11,421
expO 239 International Genomic 
Consortium
[41] Affymetrix U133v2 GEO: GSE2109 16,634
TGIF1 49 EORTC trial 10994 [5] Affymetrix U133A GEO: GSE1561 11,837
BWH 40 + 7 Brigham and Women's 
Hospital (Boston, MA, 
USA)
[14] Affymetrix U133v2 GEO: GSE3744 16,634
Small diagnostic 
platforms
TRANSBIG 253 TRANSBIG Consortium [2] Agilent AE: E-TABM-77 1,052
EMC2 180 Erasmus Medical Center [6] Affymetrix (custom) GSE3453 86
HPAZ 96 Hospital La Paz (Madrid, 
Spain)
[4] RT-PCR Appendix of [4] 61
Total 2,865 = 2,833 carcinomas + 32 nonmalignant 
breast tissues
Number of the union of all GeneIDs: 17,198
Number of GeneIDs common to genomic platforms: 1,963
Datasets UNC, STNO, UCSF, and BWH include a small number of normal breast or fibroadenoma tissue samples. AE, ArrayExpress (accession); Affymetrix, 
Affymetrix, Inc., Santa Clara, CA, USA; Agilent, Agilent Technologies, Inc., Santa Clara, CA, USA; EORTC, European Organization for Research and 
Treatment of Cancer; GEO, Gene Expression Omnibus (accession); RT-PCR, reverse transcription-polymerase chain reaction.Page 4 of 11
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To automatically assign these large numbers of tumors into the
subtypes according to the given module, we applied the
Gaussian mixture models [29] to the module scores of the
three processes. Only three natural clusters, based on multi-
modality tests, can be identified. The ER and HER2 module
scores were bimodally distributed, but the proliferation module
was not. Furthermore, the combination of the ER and HER2
module scores does not produce four clusters that would have
been observed if the scores were independent (Figure 1a).
Instead, ERBB2+ tumors showed an intermediate level of ER
module values, and we therefore did not consider the
distinction of ERBB2+ into ER+ or ER- to be supported by con-
tinuous value gene expression levels. We will refer to three
groups as ER-/HER2-, HER2+, and ER+/HER2- tumors, which
correspond roughly to the intrinsic subtypes of basal-like,
her2, and combined luminal A/B subtypes, respectively, as
defined by the Stanford group [15].
Concerning proliferation, Figure 1b shows that, while ER-/
HER2- and HER2+ tumors have mostly high proliferation
scores, ER+/HER2- tumors display a wide range of values,
Figure 2
Survival analysis of groups based on module scoresl . Kaplan-Meier analysis for distant relapse-free survival (DRFS) of systemically untreated (a) and 
treated (b) patient groups. The ER+ subgroup is split into ER+/HER2-/L and ER+/HER2-/H (low and high proliferation, respectively). Vertical bars on 
the curves are 95% confidence intervals for the Kaplan-Meier survival estimates. Forest plot representation of the 5-year survival estimates and haz-
ard ratios for DRFS of individual datasets in the systemically untreated (c) and treated (d) populations. The length of horizontal bars and the width of 
the diamonds of the 'Total' correspond to 95% confidence intervals. Missing bars are unavailable data. Multivariate analysis representation in which 
all the variables are available in systemically untreated (e) and treated (f) patients. ER, estrogen receptor; HR, hazard ratio.Page 5 of 11
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dataset UNC) and the high values typical for ER-/HER2- and
HER2+ tumors. For our further analysis, we denote the ER+/
HER2- low- and high-proliferation tumors as ER+/HER2-/L and
ER+/HER2-/H, corresponding to the luminal A and B subdivi-
sions of the intrinsic subtypes, respectively. Interestingly, we
did not see natural clustering (bimodality) in the distribution of
proliferation scores as was the case with the ER and ERBB2
modules.
The relationship between module scores and some gene
mutations could also be examined. Almost all BRCA1-mutated
tumors are confined to ER- tumors (Figure 1b), confirming the
hypothesis that ER- ('basal-like') tumors are phenocopies of
BRCA1-mutated tumors [14]. This is also supported by the
strong overexpression of LMO4, a suppressor of BRCA1
function [31], in ER- tumors. p53 mutations may appear in the
three subtypes, but mostly confined to the highly proliferative
tumors. It is not clear whether their association with ER-/
HER2- and HER2+ tumors is related to the pathways of these
receptors or is merely an indirect effect of the mutations' asso-
ciation with proliferation.
Prognostic value of the molecular subtypes according to 
the module scores
The attractiveness of gene expression prognostic signatures
for clinical applications comes from their ability to identify a
group of patients with a good survival rate that is acceptable
to spare patients from aggressive chemotherapy. Here, we
investigated whether classifications based on the easily inter-
pretable module scores could achieve such clinical relevance.
Figure 2 shows a Kaplan-Meier analysis for the DRFS of sys-
temically untreated (Figure 2a) patients and those treated (Fig-
ure 2b) with adjuvant chemotherapy and/or endocrine therapy
with available clinical information, according to four main sub-
types based on the module scores. The ER+/HER2-/L subtype
showed a much better DRFS than the three others in both
untreated and treated populations, with 90% of patients alive
at 5 years of follow-up. Because there is no statistical differ-
ence in survival between the ER-, HER2+, and ER+/HER2-/H
subtypes and because the risk of recurrence for patients in
these groups is clinically still too high, we pooled them into the
'poor' prognosis group, in contrast to the 'good' ER+/HER2-/L
subtype, for further survival analysis. The consistency of the
prognostic value across datasets is demonstrated by the for-
est plots in Figures 2c and 2d, where the results of the analysis
of individual datasets are concisely summarized by the 5-year
survival estimates and hazard ratios between the 'good' and
'poor' groups. Interestingly, the 'good' prognosis group
showed a better DRFS than the 'poor' prognosis group in both
untreated and systemically treated populations.
The interactions between the module-based risk groups and
conventional clinicopathological prognostic variables are
tested in multivariable Cox regression analysis for DRFS in
both untreated (Figure 2e) and treated (Figure 2f) populations.
The module-based classification added a strong prognostic
effect over all other clinical factors. Confirming previous stud-
ies [18,32], the effect of histological grade is much reduced
and can be explained by the refinement of intermediate grade
into two groups with very different survival rates. Interestingly,
lymph node status and tumor size remain as independent
prognostic factors.
Dissecting gene expression prognostic signatures 
according to the module scores
Although Fan and colleagues [25] noted the similarity of the
performance and patient classifications of the intrinsic sub-
types and four prognostic signatures on the same dataset,
they did not provide a biological rationale for this finding. In our
study, we performed more detailed and extensive analysis to
better understand how disparate gene lists may give rise to
potentially equivalent prognostic signatures.
Using our meta-analytical approach, we first sought to identify
individual genes that were associated with survival by calculat-
ing the meta-analytical z scores of gene-by-gene Cox regres-
sion. To gain further insight into the biological significance of
these prognostic genes, we investigated their correlation with
the coexpression module prototypes. We were able to identify
524 genes that were significantly associated with survival,
even under a stringent Bonferroni multiple testing correction
(data not shown). Of the 524 genes, 71% were strongly coex-
pressed with proliferation, 26% with ER, and 2.2% with
ERBB2 prototypes, highlighting the importance of prolifera-
tion-related genes for prognostication in breast cancer.
A similar analysis was performed with respect to several pub-
lished prognostic signatures (Table 2). Indeed, many of the
genes included in these signatures were confirmed to be indi-
vidually prognostic in the whole dataset collection (Figure 3 of
Additional data file 2). Interestingly, many of these individually
prognostic genes were also highly correlated with the prolifer-
ation module prototype and not with the other two modules,
suggesting that proliferation may be the common driving force
of several prognostic signatures.
To further demonstrate our hypothesis, we divided each signa-
ture into two 'partial signatures': one with only proliferation
genes and the other with the complementary nonproliferation
genes (Figure 3; see Figure 4 of Additional data file 2 for
detailed analysis). Interestingly, when only proliferation genes
were used, the overall performance was not degraded; in fact,
it even improved for some signatures (p53-32) in both
untreated (Figure 3a) and treated (Figure 3c) populations. In
contrast, the nonproliferation partial signatures typically
showed degraded performance (Figures 3b and 3d). These
results show that proposed signatures may contain genes that
are unnecessary or even detrimental to their performance.Page 6 of 11
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[25] to a much larger sample size and for several additional
signatures, revealing for the first time the importance of prolif-
eration genes as a common driving force behind the perform-
ance of all of the prognostic signatures studied in this
investigation.
Finally, the relationship between prognostic signatures and
the molecular classification based on the coexpression mod-
ules was investigated by looking at the risk classifications on
the plots of proliferation scores versus the molecular subtypes
shown in Figure  4 (see Figure 4 of Additional data file 2 for
analysis on all datasets). Most signatures identified the low-
proliferation subset of ER+/HER2- tumors as low-risk, whereas
almost all high-proliferation ER+, ER-/HER2-, and HER2+
tumors were classified as high-risk. These results suggest that
these prognostic signatures function mostly by identifying
tumors that have high expression of proliferation genes,
regardless of the subtyping based on ER or HER2. They still
correctly classify ER-/HER2 and HER2+ as high-risk by virtue
of elevated expression of proliferation genes.
Discussion
Several breast cancer studies have generated a large number
of arrays with complex genomic data, and an initial effort was
made to compare the prognostic performance of the intrinsic
subtypes and four signatures in one dataset [25]. In the
present meta-analysis, we analyzed data from 2,833 patients
to have the power to address the following questions: How are
different signatures related with respect to prognostication?
Should clinical, pathological, and currently used biomarkers
be integrated into this process? What is the role of individual
genes in a signature, and what is their biological meaning?
Using our meta-analytical approach, we confirmed the pres-
ence of four stable breast cancer molecular subtypes as orig-
inally reported by Perou and colleagues [33], whereas the
normal-like subtype was not verified. Both ER-/HER2- and
HER2+ subtypes were characterized by high proliferation,
whereas the ER+/HER2- subtype was divided into low- and
high-proliferation tumors with different clinical outcomes. The
widely observed prognostic powers of ER and HER2 are
therefore only indirect effects.
Furthermore, the above results have important clinical implica-
tions since they suggest that all investigated prognostic signa-
tures are equivalent. This will be further validated when the
results from the currently accruing MINDACT (Microarray in
Node-Negative Disease May Avoid Chemotherapy) [34] and
TAILORX (Trial Assigning IndividuaLized Options for Treat-
ment [Rx]) [35] trials are reported. For the ER-/HER2- and
HER2+ patients, new prognostic signatures, which do not rely
on proliferation genes, are urgently needed. Initial efforts to
improve prognosis in the above high-risk subgroups were
recently reported [36,37].
Moreover, rather than treating the signatures as black boxes,
the connection to the breast cancer biology has been eluci-
dated. Using this approach, we demonstrated that several pre-
viously reported prognostic signatures, despite the disparity in
their gene lists, carry similar information with regard to prog-
nostication. Although it may be argued that microarray meas-
urements are merely alternative ways to monitor well-known
processes such as proliferation, ER, or HER2 signaling, their
results are not perfectly concordant with conventional varia-
bles. For example, although the proliferation module score and
histological grade both aim to measure cell proliferation, the
former is more informative [18]. We observed that HER2+
tumors showed intermediate ER module activity, which is not
obvious from the traditional ER and HER2 status using con-
ventional assays. These examples suggest that the assess-
ment of several genes from a coexpression module may
provide a more accurate quantification of a whole transcrip-
tional process than using single-gene markers or histopatho-
logical variables.
Figure 3
Signature comparison. The prognostic performance of the signatures is 
compared by the forest plots of hazard ratio and plotted as vertical 
color bars for comparison. Most signatures show similar performance. 
Prognostic performance for distant relapse-free survival (DRFS) of the 
signatures using partial signatures containing only proliferation genes in 
the untreated (a) and treated (c) populations. The performance of most 
signatures is not degraded; in fact, it is improved for p53-32. Prognos-
tic performance for DRFS of the signatures using partial signatures 
containing nonproliferation genes in the untreated (b) and treated (d) 
populations.Page 7 of 11
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into those related to the extent of tumor progression (such as
lymph node status and tumor size) and those related to a
tumor's intrinsic aggressiveness (such as histological grade
and mitotic rate) and found only that the prognostic roles of
many markers, such as ER, progesterone receptor, and p53,
were overshadowed by histological grade. Our results con-
firmed these observations, as proliferation genes are even
better indicators of tumor grade [18]. The proliferation score
already contains the poor prognosis information attributable to
various sources: for example, ERBB2 amplification (with or
without BRCA1 mutation), p53 mutation, or yet unknown fac-
tors specifically affecting half of ER+ (luminal) tumors. We still
see the prognostic effect of lymph node status and tumor size,
suggesting that they influence outcome through their own
independent paths.
Despite the lack of direct prognostic impact of ER and ERBB2
genes, the coexpression modules for these processes that we
identified are still useful. Genes in the proliferation module are
already targeted by several chemotherapeutic agents, but less
Table 2
Prognostic signatures
Signature symbol Reference Associated variables in gene selection procedure Number of genes
Original probes Mapped to geneID
ONC-16 [42] Biological knowledge; refined by patient outcome 16 16
NKI-70 [19] Patient outcome 70 52
EMC-76 [21] Patient outcome, stratified by estrogen receptor status 60 + 16 48 + 12
NCH-70 [12] Patient outcome 70 69
CON-52 [43] Patient outcome, consensus 52 50
p53-32 [11] p53 mutation 32 19
CSR [24] Fibroblast core serum response 512 457
GGI-128 [18] Histological grade 128 98
CCYC [44] Periodic expression in cell cycle progression NA 126
NA, not applicable.
Figure 4
Patient classifications made by example signatures applied to representative datasets, showing that the different signatures are essentially detecting as low-risk the low-proliferation subset of ER+/ERBB2- tumors
as low-risk the low-proliferation subset of ER+/ERBB2- tumors. ER, estrogen receptor.Page 8 of 11
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treatable to some extent by hormone therapy [39] (targeting
ESR1 signaling), and HER2+ tumors by trastuzumab [40] (tar-
geting ERBB2). However, drugs specifically targeting ER-/
HER2- tumors have not yet been established. Furthermore, the
fact that many breast tumors remain unresponsive to existing
drugs warrants further searches for alternative targets, possi-
bly compensatory genes in the same pathway. Our analysis
provides lists of genes coexpressed with these two proc-
esses, and these lists should be more stable than previously
published ones because they are identified from a large data
collection from multiple platforms.
Finally, we have also shown that using coexpression modules
is a versatile tool for unifying apparently disparate results.
Although coexpression does not imply direct physical interac-
tion, the highly correlated genes in a module can be consid-
ered surrogate markers of one another and of the same
underlying transcriptional process. Consequently, newly pub-
lished signatures in the future can be perceived in the light of
well-known modules, and a new, equivalently prognostic set of
markers can be devised based on subsets of these lists.
Conclusion
In summary, this study objectively evaluates several published
signatures in independent cohorts from diverse microarray
platforms and unifies results of previous gene expression stud-
ies in breast cancer. With respect to clinical application, we
revealed connections and equivalence between traditional
prognostic factors, expression-based subtyping, and prognos-
tic signatures and provided evidence that these signatures
should be tested for their ability to spare adjuvant chemother-
apy mainly in the low-proliferation subgroup of patients with
ER+ tumors. With respect to disease biology, we consolidated
the gene lists of the major processes, providing more reliable
candidates for biomarkers and therapeutic targets than those
produced by single-dataset studies. Finally, we provided a
new methodological framework, also applicable to other dis-
eases, for using heterogeneous microarray datasets to
uncover consistent biological relationships and to consolidate
proposed signatures.
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